Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 15/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30784909 | 0.75 | KDM4E (0.47) | MAPKAPK2POLBHPGDSMN1; SMN2KDM4E | |
| SCHEMBL21193052 | 0.75 | KDM4E (0.47) | MAPKAPK2POLBHPGDSMN1; SMN2KDM4E | |
| SCHEMBL28823640 | 0.73 | AGBL2 (0.46) | MAPKAPK2POLBSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1807187 | 0.69 | MAPKAPK2 (0.33) | MAPKAPK2HPGDKDM4EALDH1A1 | |
| SCHEMBL29364954 | 0.69 | KDM4E (0.34) | MAPKAPK2HPGDKDM4EALDH1A1 | |
| SCHEMBL160005 | 0.69 | KDM4E (0.34) | MAPKAPK2HPGDKDM4EALDH1A1 | |
| SCHEMBL26621178 | 0.68 | JAK3 (0.36) | MAPKAPK2POLBHPGDSMN1; SMN2KDM4E | |
| SCHEMBL30784811 | 0.67 | HTT (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL11326255 | 0.67 | HTT (0.34) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL30689655 | 0.66 | HSP90AA1 (0.36) | MAPKAPK2POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | MAPKAPK2 1282/4885POLB 2390/4885HPGD 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.